Company intelligence / Profile preview
Onselex Pharmaceuticals
New York, New York, United Statesonselex.com ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Preclinical
01
Overview
Onselex has developed ONX‑1006, a non-toxic nanomedicine that induces apoptosis in tumor cells with minimal side effects. The company claims this could reduce pancreatic cancer death rates and achieve a 70% five-year survival rate. Human trials are being planned in Argentina to accelerate regulatory approval.
- No published clinical results yet; preclinical data suggest high efficacy and safety.
- Therapeutic areas
- Oncology
- Modalities
- Nanomedicinenanoparticle-loaded therapeutics
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Onselex Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Onselex Pharmaceuticals.